Sugi Predict

Sugi Predict / Compounds / SCHEMBL3061760

SCHEMBL3061760

SCHEMBL3061760

O=C(O)c1ccc(S(=O)(=O)Nc2cccc3cc[nH]c23)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 1/20 0.56
▸ PGR P06401 1/20 0.56
▸ NR3C2 P08235 1/20 0.56
▸ AR P10275 1/20 0.56
▸ PTPN1 P18031 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ SLC16A3 O15427 6/20 0.47
▸ KEAP1 Q14145 1/20 0.47
▸ MMP2 P08253 1/20 0.45
▸ CA12 O43570 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ ACLY P53396 1/20 0.45
▸ CYP2C9 P11712 1/20 0.44
▸ ATIC P31939 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ RECQL P46063 1/20 0.44
▸ TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3055215 0.86 NR3C1 (0.56) NR3C1PGRNR3C2ARKMT2A
SCHEMBL2367383 0.86 NR3C1 (0.65) NR3C1PGRNR3C2ARKMT2A
SCHEMBL2367735 0.82 NR3C1 (0.60) NR3C1PGRNR3C2ARCA12
SCHEMBL1984869 0.82 CA1 (0.60) NR3C1PGRNR3C2ARKMT2A
SCHEMBL2367682 0.82 NR3C1 (0.64) NR3C1PGRNR3C2ARKMT2A
SCHEMBL2403697 0.79 TUBB4A (0.61) NR3C1PGRNR3C2ARKMT2A
SCHEMBL3073814 0.79 NR3C1 (0.56) NR3C1PGRNR3C2ARKMT2A
SCHEMBL2367583 0.79 NFKBIA (0.58) NR3C1PGRNR3C2ARKMT2A
SCHEMBL3061022 0.79 GLO1 (0.58) NR3C1PGRNR3C2ARACLY
SCHEMBL12059796 0.78 KEAP1 (0.51) NR3C1PGRNR3C2ARPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834049-B2 Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-11-16 — — US disclosed
US-20100267754-A1 INTEGRIN EXPRESSION INHIBITOR WAKABAYASHI TOSHIAKI 2010-10-21 — — US disclosed
CN-100356979-C Integrin expression inhibitors EISAI CO LTD (JP) 2007-12-26 — — CN disclosed
EP-1433479-B1 APPETITE-STIMULATING AGENTS AND REMEDIES FOR ANOREXIA EISAI R&D MAN CO LTD (JP) 2007-12-05 — — EP disclosed
US-7015241-B2 Appetite-stimulating agents and remedies for anorexia EISAI CO., LTD. (JP) 2006-03-21 — — US disclosed
CN-1221533-C Heterobicyclic sulfonamide derivative and sulfonic ester derivative EISAI CO LTD (JP) 2005-10-05 — — CN disclosed
US-20050176712-A1 Integrin expression inhibitor EISAI CO., LTD. 2005-08-11 — — US disclosed
US-20040242628-A1 Appetite-stimulating agents and remedies for anorexia EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-12-02 — — US disclosed
CN-1551766-A Lymphocytic activation inhibitor and remedial agent for autoimmune disease ������������ʽ���� 2004-12-01 — — CN disclosed
US-20040235866-A1 Lymphocytic activation inhibitor and remedial agent for autoimmune disease EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-11-25 — — US disclosed
EP-1433479-A1 APPETITE-STIMULATING AGENTS AND REMEDIES FOR ANOREXIA Eisai Co., Ltd (JP) 2004-06-30 — — EP disclosed
EP-1430894-A1 LYMPHOCYTIC ACTIVATION INHIBITOR AND REMEDIAL AGENT FOR AUTOIMMUNE DISEASE Eisai Co. Ltd (JP) 2004-06-23 — — EP disclosed
CN-1491941-A Heterobicyclic sulfonamide derivative and sulfonic ester derivative ������������ʽ���� 2004-04-28 — — CN disclosed
US-20040018192-A1 Integrin expression inhibitors EISAI CO., LTD. (JP) 2004-01-29 — — US disclosed
EP-0673937-B1 BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES EISAI CO LTD (JP) 2003-11-26 — — EP disclosed
CN-1396833-A Integrin expression inhibitors EISAI CO LTD (JP) 2003-02-12 — — CN disclosed
EP-1258252-A1 INTEGRIN EXPRESSION INHIBITORS Eisai Co., Ltd. (JP) 2002-11-20 — — EP disclosed
CN-1079097-C Heterobicyclic sulfonamide derivatives and sulfonate derivatives EISAI CO LTD (JP) 2002-02-13 — — CN disclosed
CN-1114506-A Heterobicyclic sulfonamide derivatives and sulfonate derivatives EISAI CO LTD (JP) 1996-01-03 — — CN disclosed
EP-0673937-A1 BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES Eisai Co., Ltd. (JP) 1995-09-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176712-A1 Integrin expression inhibitor ITGB5, ITGB1, ITGB2 NR3C1 570/4885PGR 1305/4885NR3C2 169/4885
US-20040235866-A1 Lymphocytic activation inhibitor and remedial agent for autoimmune disease NFATC1, CHUK, CD4 NR3C1 124/4885PGR 3500/4885NR3C2 360/4885
US-20100267754-A1 INTEGRIN EXPRESSION INHIBITOR ITGB5, ITGB1, ITGB2 NR3C1 570/4885PGR 1305/4885NR3C2 169/4885
US-20040242628-A1 Appetite-stimulating agents and remedies for anorexia GHSR, CCKAR, SUCNR1 NR3C1 193/4885PGR 1357/4885NR3C2 181/4885
US-20040018192-A1 Integrin expression inhibitors ITGB1, ITGB4, ITGB5 NR3C1 614/4885PGR 1278/4885NR3C2 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.